Chapter 7. Chickenpox vaccine for adolescents and adults;Capítulo 7. Vacunación antivaricela para adolescentes y adultos

Medicina Preventiva

Volumn 15, Issue 4, 2009, Pages 5-13

  Salleras, Luís ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949410622     PISSN: 11352841     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Weller TH. Varicella-Herpes Zoster Virus. En: Evans AS, ed. Viral infections of humans. 3 ed. New York: Plenum, 1989; p. 659-83.
2. Gershon AA. Varicella-Zoster Virus: Prospects for Control. Advances in Pediatric Infectious Diseases. Mosby Year Book 1995;10:93-124.
3. a edición. Barcelona: Masson 2003; p. 311-30.
4. Wharton M. The epidemiology of varicella-zoster virus infection. Infect Dis Clin. North America 1996;10:571-81.
5. Gershon AA, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA. Vaccines. Fourh edition. Philadelphia: WB Saunders, 2004; p. 783-824.
6. Weller TH. Varicela and Herpes zoster. Changing concepts of the natural history, control and importance of a not so bening virus. N Engl J Med 1983;309:1434-40.
7. Salleras L, Salleras M, Domínguez A, Prat A, Navas E. Varicela en el adolescente y adulto: carga de la enfermedad y estrategias de prevención mediante la vacunación. Vacunas 2005;3:92-100.
8. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clinical Microbiology Reviews 2005;18:70-80.
9. Cilla G, Pérez-Trallero E, García J. Seroepidemiology of Varicella in Children from Spain. J Infect Dis 1987;156:851.
10. Salleras L, Dominguez A, Vidal J, Plans P, Salleras M, Taberner JL. Seroepidemiology of Varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 2001;19:183-8.
11. Salleras L, Domínguez A, Plans P, Costa J, Cardeñosa N, Torner N, Plasencia A. Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain). Med Micriobiol Immunol. 2008;1997:329-33.
12. Committee of Infectious Diseases of the American Academy of Pediatrics. Recommendations for the Use of Live Attenuated Varicella Vaccine. Pediatrics 1995;95:791-6.
13. CDC. Prevention of Varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45 (RR11):1-36.
14. La Russa P. Clinical manifestations of varicella. In: Arvin AM, Gershon AA editors. Varicella-zoster virus. Cambridge University Press 2000; p. 206-19.
15. Marin M, Watson TL, Chaves SS, Civen R, Watson BM, Zhang JX et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008;197 (Suppl 2):S94-S100.
16. Danovaro Holliday MC, Gordon ER, Jumaan AO, Woernle C, Judy RH, Scott Schmid D, Seward JF. High Rate of Varicella Complications among Mexican-Born Adults Alabama. Clin Infect Dis 2004;39:1633-9.
17. Gershon AA, Hambleton S. Varicella vaccine for susceptible adults: do it today. Clin Infect Diis 2004;39:1640-1.
18. Almuneef M, Memish ZA, Abbas ME, Balkhy HH. Screening healthcare workers for varicella-zoster virus: can we trust the history? Infect Control Hosp Epidemiol 2004;25:595-8.
19. Feldman S, Hughes W, Daniel C. Varicella in children with cancer: 77 cases. Pediatrics 1975;80:388-97.
20. Watson BH, Foster JA, White CJ, Laufer D. Varicella in the normal and immunocompromissed host. Bailliere's Clinical Infectious Diseases 1996;3:425-38.
21. Enders G, Miller E. Varicella and herpes zoster in pregnancy and the newborn. In: Arvin AM, Gershon AA editors. Varicella-zoster virus. Cambridge University Press 2000; p. 206-19.
22. Reynolds MA, Watson BM, Plott-Adams KK, Jumaan AO, Galil K, Maupin TJ et al. Epidemiology of varicella hospitalizations in the United States, 1995-2005. J Infect Dis 2008;197 (Suppl 2):S120-6.
23. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004;114:786-92.
24. Coplan P, Black S, Rojas C, Shinefield H, Ray P, Lewis E et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J 2001;20:641-5.
25. Gil A, Gonzalez A, Oyaguez I, San-Martín M, Carrasco P. The burden of severe varicella in Spain, 1995-2000 period. Eur J Epidemiol 2004;19:699-702.
26. Gil A, San-Martin M, Carrasco P, Gonzalez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004;22:3947-51.
27. Seward J, Galil K, Wharton M. Epidemiology of varicella. In: Arvin AM, Gershon AA editors. Varicella-zoster virus. Cambridge University Press 2000; p. 206-19.
28. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005;352:450-8.
29. Takahashi M. Vaccine development. Infect Dis Clin North Am 1996;10:469-88.
30. Asano Y. Varicella vaccine: The Japanese Experience. J Infect Dis 1996;174 (suppl 3):S310-3.
31. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glicoprotein antigen. J Med Virol 1990;32:189-93.
32. Gershon AA. Human Immune Responses to Live Attenuated Varicella Vaccine. Rev Infect Dis 1991;13 (Suppl 11);S957-9.
33. D'Hont E, Berge E, Colinet M, Duchene M, Peetermans J. Production and quality control of the OKA strain live varicella vaccine. Postgrad Med J 1985;61 (Suppl 4):53-6.
34. Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and Safety of a Live Attenuated Varicella Vaccine (OKA/SB Bio) in Healthy Children. J Infect Dis 1996;174(Suppl 3):S324-9.
35. Just M, Berger R, Luescher D. Live varicella vaccine in healthy individuals. Postgrad Med J 1985;61 (Suppl 4):129-32.
36. André FE. Summary of clinical studies with the OKA live varicella vaccine produced by Smith Kline-RIT. Biken Journal 1984;27:89-98.
37. Tan AYS, Connett CJ, Connett GJ, Quek SC, Yap HK. Use of reformulated OKA Strain varicella vaccine (SKB/OKA) in healthy children. Eur J Pediatr 1996;155:706-11.
38. Ramkisoon A, Coovadia HM, Yugnundan P, Haffejer IE, Meurice F, Vandervoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. S. Afr. Med J 1995;85:1295-8.
39. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78 (Suppl):748-56.
40. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ et al. Varicella vaccine (Varivax) in healthy children and adolescents. Results froma clinical trails, 1987 to 1989. Pediatrics 1991;87:604-10.
41. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D et al. Humoral and cell mediate immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995;20:316-9.
42. Ellis RW. Varicella vaccine. Vaccine 1995;13:1387-8.
43. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein R. Varicella vaccine: the American experience. J Infect Dis 1992;166 (Suppl):S63-8.
44. Ndumbe PM, Cradock-Watson JR, Mac Queen S, Dunn H, Andre F, Davis EG, Dudgeon JA, Levinsky RJ. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1992;165:852-8.
45. Tlesnik V, Prikazsky V, Petvaldsk L. Protective effect of vaccination against chickenpox. Epidemiol Mikrobiol Imunol 2000;49:143-7.
46. Barzaga NC, Florece RH, Bock HL. Reactogenicity and Immunogenicity of a varicella vaccine in Healthy seronegative and seropositive subjects. South East Asian J Trop Med Public Health 2002;33:259-67.
47. Kusowon P, Sutra S, Kosalaraska P. Advantage of a two-dose versus one dose varicella vaccine in healthy non-immune teeangers and young adults. Southeast Asian J Trop Med Public Health 2004;35:697-701.
48. Arberter AM. Clinical trials of varicella vaccine in healthy adolescents and adults. Infect Dis Clin North America 1996;10:609-15.
49. Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuatd varicella vaccine. J Infect Dis 1988;158:132-7.
50. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitsgerald AJ et al. Live attenuated varicella vaccine: efficacy trial in healthy children. N Engl J Med 1984;310:1409-15.
51. Varis T, Vesikari T. Efficacy of High-Titer Attenuated Varicella Vaccine in Healthy Young Children. J Infect Dis 1996;174 (Suppl 3):S330-4.
52. Kuter BJ, Weibel RE, Guess HA, Mathews H, Morton DM, Neff BJ et al. Oka/Merk varicella vaccine in healthy children: final report of a 2-year efficacy stydy and 7-year follow up studies. Vaccine 1991;9:643-7.
53. Weibel RE, Kuter BJ, Neff BJ, Rothenberger LA, Fitzgerald AJ, Connor KA et al. Live Oka/Merck varicella vaccine in healthy children: further clinical and laboratory assessment. JAMA 1985;254:2435-9.
54. White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North America 1996;10:595-607.
55. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US program: a review. J Infect Dis 2008; 197 (Suppl 2);S82-9.
56. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495-9.
57. Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day care setting. Pediatric Infect Dis J 1999;18:1047-50.
58. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C et al. Postexposure effectiveness of varicella vaccine. Pediatrics 2000;105:84-8.
59. Vazquez M, La Russa PS, Gershon AA, Steinberg SP, Freudingman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Egl J Med 2001;344:955-60.
60. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Yonger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002;186:102-5.
61. TugweLL BD, Lee LE, Lorber K, Gillette H, Lorber EM, Hedberg K et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004;113:455-9.
62. Shapiro ED, LaRussa PS. Vaccination for varicella. Just do it! JAMA 1997;278:1529-30.
63. Seward KF-Watson BM. Peterson CL, Mascola L, Pelosi JW, Zhang JX et al. Varicella disease after the introduction of varicella vaccine in the United States 1995-2000. JAMA 2002;287:606-11.
64. Passwell JH, Hemo B, Levi Y, Ramon R, Friedman N, Lerner-Geva L. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediatr Infect Dis J 2004;23:221-6.
65. Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J 2005;24:434-7.
66. Mullooly JP, Maher JE, Drew L, Schuler R, Hu W. Evaluation of the impact of an HMO 's varicella vaccination program on incidence of varicella. Vaccine 2004;22:1480-5.
67. Seward JF. Update on varicella. Ped Infect Dis J 2001;20:619-21.
68. st century. Pediatr Infect Dis J 2004;23:871-2.
69. Marin M, Meissner HC, Seward J. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008;122:e744-51.
70. Centers for Disease Control and Prevention (CDC). Decline in annual incidence of varicella-selected states, 1990-2001. MMWR 2003;52:884-5.
71. Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM e at. Varicella-zoster virus infection in Australia. Aust N Z J Public Health 1998;22:413-8. Erratum in: Aust N Z J Public Health 1998;22:630.
72. Lam MS, Chew SK, Allen DM, Monterio EH. Fatal varicella infectionS in Singapore. Singapore Med J 1993;34:213-5.
73. Bramley JC, Jones IG. Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health 2000;3:282-7.
74. Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 2002;129:599-606.
75. Fairley CK, Miller E. Varicella-zoster virus epidemiology - a changing scene? J Infect Dis 1996;174 (Suppl 3):S314-9.
76. Rawson H, Crampin A, Noah N. Deaths form chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 2001;323:1091-3.
77. Quian J, Romero C, Dalorso P, Cerisola A, Rüttiman R. Resultados de la vacunación universal a niños de un año con vacuna de la varicela en Montevideo, Uruguay. Arch Ped Urug 2003;74:259-67.
78. rd Annual Meeting of the European Society for Pediatric Infectious Diseases. ESPID Valencia (Spain). May 18-20, 2005.
79. rd Annual Meeting of the European Society for Pediatric Infectious Diseases. ESPID Valencia (Spain). May 18-20, 2005.
80. Guide for Adult Immunization. Third edition. American College of Physicians. Philadelphia, Pennsilvania,1994.
81. Salleras L, Salleras M, Prat A, Domínguez A, Garrido P. Vacunas frente al virus de la varicela zoster. Enferm Infecc Microbiol Clin 2007;25(Suppl 5):S25-47.
82. Heininger U, Seward JF. Varicella. Lancet 2006;368:1365-76.
83. Gershon AA. Varicella-zoster virus infections. Pediatr Rev 2008;29:5-11.
84. Moraga R, Campins M. Vacuna de la varicela. Una inmunización del niño y del adutlo. Enfer Infec Microbiol Clin 2000;18:516-8.
85. Plans P, Costa J, Espuñes J, Plasencia A, Salleras L. Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women of childbearing age. BJOG 2007;114:1122-7.
86. Díez-Domingo J, Gil A, San-Martín M, González A, Esteban J, Baldo JM et al. Seroprevalence of varicella among children and adolescents in Valencia, Spain. Reliability of the parent's reported history and the medical file for identification of potential candidates for vaccination. Human Vaccines 2005;1:201-8.